HER2-positive breast cancer

May 21, 2018

Herceptin Treatment Time Could be Halved for Breast Cancer, Phase 3 Trial Finds

News

A shorter Herceptin (trastuzumab) treatment — six months instead of the standard 12 months — is equally effective and carries fewer heart-related adverse effects, a Phase 3 clinical trial found. The results ... Read more

March 26, 2018March 26, 2018

Sentinel Lymph Node Biopsies May Not Be Needed with Prior Chemo, Study Suggests

News

Removing lymph nodes to check for signs of breast cancer may not be necessary for women with triple-negative or HER2-positive breast cancer who responded well to chemotherapy before surgery to ... Read more

September 29, 2017September 29, 2017

Nerlynx Delays Invasive Disease in Breast Cancer Patients Treated with Herceptin, ExteNET Trial Shows

News

Researchers found an increase in invasive disease-free survival (iDFS) in patients with early-stage breast cancer treated with Puma Biotechnology’s Nerlynx (neratinib) after initial treatment with Herceptin (trastuzumab). Quality of life was ... Read more

July 18, 2017

Nerlynx Approved by FDA for HER2-positive Breast Cancer Patients to Reduce Risk of Recurrence

News

The U.S. Food and Drug Administration (FDA) approved Puma Biotechnology‘s Nerlynx (neratinib) as an extended adjuvant treatment of early-stage, HER2-positive breast cancer. This means that Nerlynx is the first extended adjuvant therapy for ... Read more

March 6, 2017March 6, 2017

Shorter Herceptin Treatment Cheaper, Better for HER2-Positive Breast Cancer Patients

News

Taking Herceptin (trastuzumab) for nine weeks is just as effective in HER2-positive breast cancer patients as taking the same drug for 12 months — as is currently recommended. A British study now ... Read more

January 12, 2017

Dentritic-cell Vaccine Shows Promise in HER2-positive Early-stage Breast Cancer

News

A new cancer vaccine that uses a patient’s own immune-regulating dendritic cells to target the HER2 protein can activate the immune system and cause regression of early-stage HER2-positive breast cancer, according ... Read more

October 17, 2016

Researchers Develop Vaccines to Fight HER2-Positive Breast Cancers

News

Vaccines containing specific molecules expressed by breast cancer cells can alert the immune system for the presence of the cells and trigger a response to eliminate them, according to a study ... Read more

June 7, 2016June 8, 2016

All About ER Positive, HER2 Negative Breast Cancer

News

About one in eight women in the United States will develop breast cancer, according to commonly used statistics. But other reports indicate that breast cancer rates are on the decline, likely ... Read more

March 23, 2016March 23, 2016

HER2 Positive Breast Cancers Drastically Reduced Before Surgery with 2-Drug Combo, Study Shows

News

A clinical trial funded by Cancer Research UK indicates that a drug combination of lapatinib, a protein tyrosine kinase inhibitor, and trastuzumab, a monoclonal antibody, before surgery can quickly shrink and even ... Read more

May 1, 2015May 1, 2015

Researchers Discover Sequence in HER2 Protein Responsible For Cancer Cell Proliferation

Breast Cancer News, News

In a new study entitled “Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling,” researchers discover a key sequence in HER2 protein that, once disrupted, ... Read more